An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough. Issue 3 (20th September 2021)

• Record Type: Journal Article
• Authors: Abdulqawi, Rayid; Satia, Imran; Holt, Kimberley J.; Dockry, Rachel; Sen, Shilpi; Smith, Jaclyn A.
• Is Part Of: ERJ open research. Volume 7:Issue 3(2021)
• Publication Date: 2021-09-20
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00447-2021
• Languages: English
• ISSNs: 2312-0541

Abstract

Refractory chronic cough (RCC) is defined as cough lasting longer than 8 weeks either in the absence of an identifiable underlying cause or that remains resistant to treating any potential underlying causes [1]. Affected patients have a poor quality of life and suffer from fatigue, disturbed sleep, incontinence, frustration, anxiety, and depression [2]. Despite being a debilitating condition, no licensed treatment is available. Blocking NMDA receptors with memantine in refractory chronic cough patients is poorly tolerated and demonstrates no improvement in cough https://bit.ly/3kgx2g1